Phoenix, AZ – According to filings with the U.S. Securities and Exchange Commission, OncoMyx Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Steven Potts played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OncoMyx Therapeutics
OncoMyx Therapeutics targets hematologic and solid tumors with unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. The myxoma program is the result of two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are in development for both hematology (myeloma and AML) as well as solid tumors. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.

To learn more about OncoMyx Therapeutics, visit http://www.oncomyx.com/

Contact:
Steven Potts, President and Chief Executive Officer
602-567-8064
https://www.linkedin.com/in/steven-potts/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved